Farmak International maintained a strong pace of portfolio expansion throughout the summer of 2026, completing launches and re-launches across Europe, Latin America, the Middle East and Southeast Asia. The products covered several therapeutic areas, including hospital and acute care, CNS, ophthalmology, cardiometabolic care and diabetes, diagnostic imaging, and vitamins. Between June and August, the company completed 14 new launches and 3 re-launches. Key developments included: ▶ Gadobutrol launches in Poland, Czechia and Slovakia, expanding the diagnostic imaging portfolio; ▶ Propofol launch in Kuwait and re-launch in Mexico, together with further hospital portfolio expansion through vasopressin, dexamethasone and tranexamic acid; ▶ new CNS and ophthalmology products, including atomoxetine in the UK and latanoprost in Mexico; ▶ expansion of the cardiometabolic and diabetes portfolio with dapagliflozin, metformin and ticagrelor; ▶ the launch of Vitamin B1+B6+B12 injectable solution in Vietnam. The UK was the most active market during the summer, with six launches across several therapeutic areas. Hospital and acute care products represented the largest area of activity, reflecting continued development of this strategically important part of the Farmak International portfolio. The results also demonstrate the continuous nature of launch management, where multiple projects move forward simultaneously across markets and functions throughout the year. [press_quote] The 17 summer launches reflect the continued progress of Farmak International’s portfolio development and the company’s ability to bring multiple products to market across different countries and therapeutic areas.
